Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study

Primary or secondary mutations in KIT or platelet-derived growth factor receptor alpha (PDGFRA) underlie tyrosine kinase inhibitor resistance in most GI stromal tumors (GISTs). Avapritinib selectively and potently inhibits KIT- and PDGFRA-mutant kinases. In the phase I NAVIGATOR study (NCT02508532),...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Yoon-Koo, George, Suzanne, Jones, Robin L., Rutkowski, Piotr, Shen, Lin, Mir, Olivier, Patel, Shreyaskumar, Zhou, Yongjian, von Mehren, Margaret, Hohenberger, Peter, Villalobos, Victor, Brahmi, Mehdi, Tap, William D., Trent, Jonathan, Pantaleo, Maria A., Schöffski, Patrick, He, Kevin, Hew, Paggy, Newberry, Kate, Roche, Maria, Heinrich, Michael C., Bauer, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478403/
https://www.ncbi.nlm.nih.gov/pubmed/34343033
http://dx.doi.org/10.1200/JCO.21.00217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478403/
https://www.ncbi.nlm.nih.gov/pubmed/34343033
http://dx.doi.org/10.1200/JCO.21.00217

Ejemplares similares